Rallybio (RLYB) Other Non-Current Assets (2025 - 2026)

Rallybio (RLYB) posted Other Non-Current Assets of $810000.0 for Q1 2026, little changed sequentially from $810000.0 in Q4 2025.

Rallybio (RLYB) Other Non-Current Assets (2025 - 2026) Analysis & Trends

Rallybio has reported Other Non-Current Assets for 2 years, with the latest figure at $810000.0 in Q1 2026.

Quarterly Other Non-Current Assets changed N/A year-over-year to $810000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $810000.0 (changed N/A YoY) and the FY2025 annual result came in at $810000.0, changed N/A from the prior year.
Other Non-Current Assets held at $810000.0 in Q1 2026 per RLYB's latest filing, from $810000.0 in the prior quarter.
Over five years, Other Non-Current Assets peaked at $810000.0 in Q3 2025 and troughed at $810000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	124.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	618.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	109.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	65.13 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	202.31 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	104.44 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	62.96 Mn
10	Rallybio	94.61 Mn	94.61 Mn	-	810,000.00

Download Data